HASBROUCK HEIGHTS, N.J., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX - News) today announced that new clinical trial data concerning the safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the North Central Section of the American Urological Association Meeting in Rancho Mirage, CA October 19, 2011. The paper is authored by leading independent clinical research investigators participating in the U.S. clinical trials of NX-1207.
<<< plus the fact they no longer are engaged in small money raises anymore. This tells me they have a strong hand- >>>
ummmm... maybe the fact that they got $13 million from Recordati at yearend is the reason they aren't doing small money raises... good grief man..
and how are you privy to the nature and extent of the bidding process??
New investors not welcome to the current U.S. partner bidding process- because its been closed for about 3 months. We are not far from good action here- the NX-1207 has Nymox in a very strong position to make sure shareholders will be well compensated in a much faster time period than you think.
<<< why announce now to present in october. why? why? >>>
duuuh.. they have 16 months between now and when they might file an NDA for the drug, and that's an optimistic assumption. They did the Recordati deal for Europe to garner proof of concept and some cash. They are in no hurry to sign a US licensee, unless someone will pay full value now.
SO there is NOTHING going on. This is why you announce an October presentation now, just to keep people interested.......